Himadri Speciality Chemical Limited (HSCL) Operating Income 2022–TTM

Name: Himadri Speciality Chemical Limited (HSCL) operating income history 2022-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-11-02

Himadri Speciality Chemical Limited annual operating income for fiscal TTM was ₹13.9 billion, an increase of 48.3% from ₹9.4 billion in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

HSCL Annual Operating Income

Operating Income (annual)	TTM → 2026-09-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Operating Income (EBIT)	₹13.9B	₹9.4B	₹7.9B	₹5.9B	₹3.7B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HSCL Quarterly Operating Income

Operating Income (quarterly)	2026-09-30	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Operating Income (EBIT)	₹2.9B	₹2.9B	₹4.3B	₹3.7B	₹2.2B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Operating Income at Comparable Companies

ACUTAAS Operating Income — Acutaas Chemicals Limited
7966 Operating Income — LINTEC Corporation
4966 Operating Income — C.Uyemura & Co.,Ltd.
4043 Operating Income — Tokuyama Corporation
4634 Operating Income — artience Co., Ltd.
8098 Operating Income — Inabata & Co.,Ltd.

More HSCL metrics: Revenue · Gross Profit · Net Income · EPS · Free Cash Flow

All HSCL financial statements → Interactive HSCL charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.